Key Highlights
- venBio Fund V closes with $528 million in capital commitments.
- Oversubscribed fundraising initiated in mid-April.
- Limited partners include sovereign wealth funds, corporate pensions, and more.
- Nine FDA drug approvals achieved in six years by portfolio companies.
- Dr. Yvonne Yamanaka promoted to Partner with Fund V’s closing.
Source: Business Wire
Notable Quotes
- “With a highly concentrated portfolio and active involvement in each company, we are proud to have helped build companies that have achieved nine FDA drug approvals over the past six years, with many more generating promising clinical efficacy and safety data.” — Dr. Aaron Royston, Managing Partner at venBio
- “Our portfolio is directly impacting patient lives, and we could not have achieved this without the ongoing commitment from our limited partners. Fund V is structured to enable us to continue our proven approach of being highly selective in company building, while doubling down on winners around key inflection points, including in crossover rounds and at IPO.” — Dr. Corey Goodman, Managing Partner at venBio
- “In structuring Fund V, our primary goal was to maintain consistency in our strategy, core team and investment discipline, and we look forward to her continued contributions to the firm.” — Dr. Richard Gaster, Managing Partner at venBio
SoHC's Take
venBio’s successful closing of its fifth venture capital fund underscores the firm’s robust strategy and strong track record in the life sciences sector. By surpassing its fundraising target and securing commitments from a diverse group of institutional investors, venBio demonstrates its ability to attract significant capital. The firm’s focus on biopharmaceuticals that address unmet medical needs and its active involvement in portfolio companies have clearly paid off, as evidenced by nine FDA drug approvals in recent years. The promotion of Dr. Yvonne Yamanaka to Partner reflects venBio’s commitment to maintaining a consistent and effective team, poised to continue driving impactful investments and advancements in the life sciences industry.
